综述:乳糜性腹水的诊断方法与当前管理
本文综述乳糜性腹水的诊断方法与当前管理。乳糜性腹水占腹水不足1%,由淋巴系统创伤或梗阻导致富含甘油三酯的乳糜液漏入腹腔,最常见病因为恶性肿瘤、肝硬化和腹部手术创伤。腹水甘油三酯浓度高于200 mg/dL符合乳糜性腹水;治疗以处理病因为基础并给予营养支持,保守治疗失败时可考虑奥曲肽/生长抑素类似物、手术结扎、栓塞及肝硬化患者经颈静脉肝内门体分流术。
要点
- 腹水甘油三酯浓度高于200 mg/dL符合乳糜性腹水。
- 成人乳糜性腹水多由恶性肿瘤和肝硬化引起,儿童多为先天性淋巴管疾病。
- 治疗以营养优化和病因处理为基石,保守治疗失败可考虑奥曲肽/生长抑素类似物、手术结扎、栓塞及肝硬化患者经颈静脉肝内门体分流术。
核心结论
- 成人乳糜性腹水多由恶性肿瘤和肝硬化引起,儿童多为先天性淋巴管疾病。
- 营养优化和病因处理是治疗的基石。
- 保守治疗失败时,可考虑奥曲肽/生长抑素类似物、手术结扎、栓塞及肝硬化患者经颈静脉肝内门体分流术。
研究设计与样本
- 文献综述,使用PubMed检索,关键词包括「乳糜」、「腹水」、「肝硬化」、「病理生理」、「营养治疗」、「腹腔穿刺」、「经颈静脉肝内门体分流术」和「TIPSS」,仅纳入英文文献。
主要发现
- 乳糜性腹水由淋巴系统创伤或梗阻导致胸导管或肠淋巴液漏入腹腔,形成富含甘油三酯的乳白色液体。
- 最常见病因为恶性肿瘤、肝硬化和腹部手术后的创伤。
- 乳糜性腹水可导致乳糜液丢失,引起营养、免疫和代谢缺陷。
- 腹水甘油三酯浓度高于200 mg/dL符合乳糜性腹水。
关键数值与推荐
- 腹水甘油三酯浓度高于200 mg/dL符合乳糜性腹水。
临床怎么用
- 治疗基于病因管理和营养支持。
- 保守治疗失败时,可考虑奥曲肽/生长抑素类似物、手术结扎、栓塞及肝硬化患者经颈静脉肝内门体分流术。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chylous ascites is rare, accounting for less than 1% of cases. An appropriate and stepwise approach to its diagnosis and management is of key importance. AIM: To review the current diagnostic approach and management of chylous ascites. METHODS: A literature search was conducted using PubMed using the key words 'chylous', 'ascites', 'cirrhosis', 'pathophysiology', 'nutritional therapy', 'paracentesis", "transjugular intrahepatic portosystemic shunt" and "TIPSS'. Only articles in English were included. RESULTS: Chylous ascites is caused by the traumatic or obstructive disruption of the lymphatic system that leads to extravasation of thoracic or intestinal lymph into the abdominal space and the accumulation of a milky fluid rich in triglycerides. The most common causes are malignancy, cirrhosis and trauma after abdominal surgery. This condition can lead to chyle depletion, which results in nutritional, immunologic and metabolic deficiencies. An ascitic triglyceride concentration above 200 mg/dL is consistent with chylous ascites. Treatment is based on management of the underlying cause and nutritional support. CONCLUSIONS: Chylous ascites is mostly due to malignancy and cirrhosis in adults, and congenital lymphatic disorders in children. Treatment with nutritional optimization and management of the underlying etiology are the cornerstones of therapy. When conservative measures fail, other interventions such as octreotide/somatostatin analogues, surgical ligation, embolization and transjugular intrahepatic portosystemic shunt in patients with cirrhosis can be considered.
引用
- Lizaola B, Bonder A, Trivedi HD, et al. Review article: the diagnostic approach and current management of chylous ascites. Aliment Pharmacol Ther. 2017. PMID: 28892178. doi:10.1111/apt.14284
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。